This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Stoke Therapeutics has finalized plans for a Phase ...
The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback